Xinfumectin Injection

This product is a non-specific drug for the cell cycle and is most sensitive to the first half of the G1 phase, which is equivalent to the time of mRNA synthesis. Its mechanism of action is to bind to DNA, inhibit RNA polymerase using DNA as a template, and thus inhibit RNA synthesis. The binding method may be that its chromophore is embedded between the base pairs of DNA, while its peptide chain is located in the minor groove of the DNA double helix, hindering the RNA polymerase from moving along the DNA molecule. The inhibitory effect of this product on RNA synthesis is mainly the extension of the RNA chain rather than affecting its initiation. This product selectively binds to guanine in DNA and does not bind to RNA lacking guanine bases. This product cannot prevent DNA replication, because DNA polymerase can cause local denaturation of DNA (such as unwinding of the double helix) right in front of it, which can cause this product to dissolve faster.

Sinoformin

This product is a yellow-green clear liquid.

Used to treat malignant tumors such as malignant hydatidiform mole, choriocarcinoma, Wilms tumor, soft tissue sarcoma, Ewing sarcoma, malignant lymphoma, neuroblastoma, testicular tumors, etc.

Intravenous injection. The dosage depends on the patient's sensitivity to this product and the clinical use method. Systemic medication: The general dose is 300-400 μg per day (6-10 μg/kg per day), dissolved in 250-500 ml of 5% glucose solution, intravenous drip for 4-5 hours, 10-12 consecutive days as a course of treatment, and the total dose is generally about 3600-6000 μg. The second course of treatment is repeated about 2 weeks apart, and the daily dose can also be reduced as appropriate to extend the course of treatment. Combination therapy: 1. Combined with vincristine and doxorubicin to treat Wilms tumor; 2. Combined with cyclophosphamide, vinblastine, bleomycin, and cisplatin to treat testicular tumors; 3. Combined with doxorubicin, cyclophosphamide, and vincristine to treat soft tissue sarcoma and Ewing sarcoma; It can also be used in combined chemotherapy regimens for the treatment of malignant lymphoma. 4 Combined with radiotherapy, it can increase the sensitivity of tumors to radiotherapy, concentrate and retain in nucleated cells, and hinder radiorepair.

1 Bone marrow suppression: A significant decrease in white blood cells and platelets may occur, usually 7 to 14 days after medication. 2 Gastrointestinal reactions: Manifested as loss of appetite, nausea, vomiting, diarrhea, and a few oral ulcers. 3 Local reactions: Intravenous injection can cause phlebitis, and leakage outside the blood vessels can cause tissue necrosis. 4 Others: A small number of patients experience dizziness, fatigue, bone and joint pain, liver function damage, electrocardiogram changes, hair loss, etc.

Patients who are allergic to any component of this product.

Not yet clear.

Keep in dark and cool place.

5ml:0.1mg

Shanxi PUDE Pharmaceutical Co., Ltd.

• Founded in:

  1995-09-13

• Address:

  The First Pharmaceutical Park, Datong Economic and Technological Development Zone, Shanxi Province

• Tax NO.:

  91140200602167297K

• Registered Funds:

  138.8 million yuan

• Website:

  Log in to view

• Email:

  Log in to view